Navigation Links
Barry D. Rutherford, M.D. presented with Master Clinical Operator Award at TCT 2012
Date:10/26/2012

MIAMI, FL OCTOBER 26, 2012 Barry D. Rutherford, MD, a world renowned interventional cardiologist, was presented the TCT 2012 Geoffrey O. Hartzler Master Clinical Operator Award in a ceremony held today during the 24th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation (CRF). The award is given each year to a physician who has advanced the field of interventional cardiovascular medicine through technical excellence and innovation.

An early mentor of Dr. Hartzler at the Mayo Clinic in Rochester, Minnesota, and later a colleague of his at the Saint Luke's Mid America Heart Institute in Kansas City, Missouri, Dr. Rutherford is known for his expertise in the development of techniques for direct balloon angioplasty in acute myocardial infarction and multi-vessel angioplasty. Among his current research interests are the development of new procedures for the treatment of chronic total occlusions in coronary arteries and for the management of acute myocardial infarction.

Dr. Rutherford has also devoted much of his career to physician training and education, teaching countless numbers of physicians over the years. In addition to serving as the principal investigator of a number of clinical trials, Dr. Rutherford has authored more than 200 abstracts and publications in peer reviewed journals and has delivered more than 230 invited lectures around the world.

TCT Directors, Gregg W. Stone, MD and Martin B. Leon, MD jointly presented the award, which recognizes technical skill and expertise. Dr. Leon is the Founder of CRF and Professor of Medicine at Columbia University College of Physicians and Surgeons and Director of the Center for Interventional Vascular Therapy at NewYork-Presbyterian Hospital/Columbia University Medical Center. Dr. Stone is Professor of Medicine at Columbia University College of Physicians and Surgeons and Director of Cardiovascular Research and Education at the Center for Interventional Vascular Therapy at NewYork-Presbyterian Hospital/Columbia University Medical Center. Both serve as Co-Directors of the Medical Research and Education Division at CRF, and direct the annual TCT scientific sessions.

"Dr. Rutherford is highly deserving of the TCT 2012 Geoffrey O. Hartzler Master Clinical Operator Award," said Dr. Stone. "His long-standing commitment to primary PCI and multivessel intervention, and technical expertise in CTO angioplasty have helped to expand the field of interventional cardiovascular medicine and provided physicians with new, more effective ways to treat patients."

"Dr. Rutherford continues to develop innovative techniques and devices for patients with cardiovascular disease, in addition to serving as mentor and teacher to the next generation of interventional cardiologists," Dr. Leon added.

Dr. Rutherford is currently the Director of the Interventional Cardiology Research Program at St. Luke's Mid America Heart Institute in Kansas City, Missouri. He is also a Professor of Medicine at the University of Missouri in Kansas City. Prior to his current position, Dr. Rutherford was consulting cardiologist at the Mayo Clinic, and Director of the Coronary Care Unit at St. Mary's Hospital in Rochester, Minnesota where he initiated research into pulmonary artery pressure during acute myocardial infarction and computer assisted patient records in the intensive care unit.

Dr. Rutherford earned his medical degree at Otago University Medical School (Dunedin, New Zealand) in 1963 and completed his residency training at the Mayo Graduate School of Medicine and Mayo Foundation for Cardiovascular Diseases.


'/>"/>
Contact: Judy Romero
jromero@crf.org
Cardiovascular Research Foundation
Source:Eurekalert

Related medicine news :

1. Renu Virmani, M.D. presented with 2012 TCT Career Achievement Award
2. Results of the AIDA STEMI MRI sub-study presented at TCT 2012
3. Results of the PC trial presented at TCT 2012
4. Results of the POSEIDON trial presented at TCT 2012
5. 1-year results of ADAPT-DES presented at TCT 2012
6. CRF announces late breaking trials and first report investigations to be presented at TCT 2012
7. New clinical guidelines for managing hypothyroid disease presented in Thyroid Journal
8. Research presented at TCT 2012 will have significant impact on interventional cardiology
9. Typical IBD patients not represented in research studies
10. Robotic surgery outcomes data presented at head and neck cancer annual meeting
11. Special issue of Cell Transplantation features research presented at IANR
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... (PRWEB) , ... February 24, 2017 , ... The International ... 7th annual “Imagine Me Beyond What You See” body image mannequin art competition. Selected ... will be showcased and the winner revealed at the 31st annual iaedp Symposium, March ...
(Date:2/24/2017)... ... February 24, 2017 , ... Castle Farms, ... their Military Wedding Giveaway, with the winning couple announced on Feb. 14, 2017, ... generously donated from local vendors: A Matter of Taste, Ryan Rousseau Enterprises, A ...
(Date:2/23/2017)... ... February 23, 2017 , ... Rare Disease Report®, which ... participating in Rare Disease Day events, hosted by the Rare Disease Legislative Advocates ... a website, weekly e-newsletter and quarterly publication, will be conducting interviews with patients ...
(Date:2/23/2017)... ... 23, 2017 , ... EBSCO Information Services (EBSCO) ... for Health and Care Excellence (NICE) framework. The agreement allows purchasers from ... to search, order and purchase medical and healthcare-related content through GOBI ®, ...
(Date:2/23/2017)... ... February 23, 2017 , ... ... today that it will soon begin franchising throughout the U.S. starting this spring. ... help bring the practice of meditation mainstream. Current Meditation will be the first ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... , Australie, le 24 février 2017 ITL Limited, ( ... diversifiée innovante, est ravie d,annoncer les excellents résultats semestriels ... période précédente correspondante. Une présentation complète « Résultats et mise ... consultée ici . Faits marquants ... 2,12 millions $ (Déc. 2015 : 1,04 million $ ; en hausse de 104 %) ...
(Date:2/24/2017)... 23, 2017 Non-alcoholic steatohepataitis (NASH) ... various drugs being developed for the treatment ... drugs that are in various phases of ... focuses on novel pharmacologic drugs & regenerative ... therapies, recombinant proteins and RNA-based therapeutics, but ...
(Date:2/24/2017)... 24, 2017  Xynomic Pharmaceuticals, Inc., an oncology drug ... has acquired exclusive worldwide rights to develop, manufacture ... inhibitor targeting hematological and solid tumors. ... and 2 clinical trials of Abexinostat in US, ... already been completed, demonstrating that Abexinostat is clinically ...
Breaking Medicine Technology: